** Shares of cancer test developer Exact Sciences EXAS.O rise ~9% to $60 premarket
** Co's colon cancer screening test receives 16% higher pricing for government-backed Medicare plans for those aged 65 years and older
** Next-generation version of EXAS' non-invasive stool screening test, Cologuard Plus, receives ~16% increase in Medicare reimbursement price, compared with its original version
** "We believe it strengthens the thesis around margin leverage and sets up EXAS to exceed the 20% EBITDA margin by 2027," Piper Sandler analysts say
** Up to last close, stock down ~26% YTD
(Reporting by Mariam Sunny in Bengaluru)
((Mariam.ESunny@thomsonreuters.com;))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。